David Lee, MD
Glaucoma Specialist · Houston, TXNPI 1104840016
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,472 of the $17,036 with a category attached, or 67.3%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 82.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $9,449 and has fallen 92.9% since, to $669 in 2025. Among glaucoma specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $191.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$14K
- Bausch & Lomb Americas Inc.$473
- AbbVie$416
- NEW World Medical,inc.$375
- Lumenis BE Inc$321
- Aerie Pharmaceuticals, Inc.$259
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$11,47267%
- Travel & lodging$1,62910%
- Food & beverage$3,93623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 51 | $14,072 |
| Bausch & Lomb Americas Inc. | 9 | $473 |
| AbbVie(2 entities) | 4 | $416 |
| NEW World Medical,inc. | 2 | $375 |
| Lumenis BE Inc | 1 | $321 |
| Aerie Pharmaceuticals, Inc. | 3 | $259 |
| Regeneron Healthcare Solutions, Inc. | 2 | $238 |
| Oyster Point Pharma, Inc. | 3 | $182 |
| Genentech USA, Inc. | 1 | $118 |
| Amgen | 2 | $115 |
| Eyepoint US, Inc. | 1 | $111 |
| Spark Therapeutics, Inc. | 1 | $82 |
| Johnson & Johnson | 1 | $81 |
| Maculogix, Inc. | 1 | $50 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Tarsus Pharmaceuticals, Inc. | 2 | $35 |
| Alcon | 2 | $32 |
| Glaukos Corporation | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$12,854
- STELLARIS$435
- LOTEMAX SM$381
- M22$321
- Rhopressa$247
- Rocklatan$247
- EYLEA$238
- Kahook Dual Blade$232
- Clearpath$232
- Ahmed Glaucoma Valve$232
- Streamline$232
- Via360$232
- MIEBO$224
- SUSVIMO$118
- PROLENSA$116
- ZYLET$116
- ENVISTA TORIC$116
- DEXYCU$111
- enVista MX60 IOL$106
- TYRVAYA$103
How this compares
$17,036 in reported general payments places this provider in the 90th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 104 | $82,323 |
| XiidraLifitegrast | 30 | $33,901 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 185 | $33,854 |
| RocklatanNetarsudil Mesylat/Latanoprost | 73 | $31,872 |
| CombiganBrimonidine Tartrate/Timolol | 80 | $29,856 |
| LumiganBimatoprost | 52 | $27,612 |
| VyzultaLatanoprostene Bunod | 56 | $27,036 |
| Cyclosporine | 50 | $18,761 |
| Travoprost | 62 | $12,797 |
| Brimonidine Tartrate | 112 | $9,702 |
| Latanoprost | 759 | $8,743 |
| RhopressaNetarsudil Mesylate | 16 | $6,689 |
| AzoptBrinzolamide | 12 | $6,333 |
| Acetazolamide ErAcetazolamide | 104 | $6,027 |
| Brinzolamide | 26 | $4,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $416 | $139,791236 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $473 | $60,93786 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $259 | $38,56189 claims |
| AlconAzopt, Simbrinza | $32 | $10,18126 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $14,072 | $3,07214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Houston
- Robert FeldmanHouston$31K
- Patrick WuHouston$11K
- Elza RachidHouston$4K
- Adam VandenlangenbergHouston$3K
- Ruchi ShahHouston$1K
- Shivani KamatDallas$164K
- Amenze OriaifoAustin$18K
- Nicholas GurneyFt Worth$13K
- Irina VoloskoAustin$11K
- Logan VincentTyler$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.